<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117454</article-id><article-id pub-id-type="publisher-id">ACM-43987</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_50766283.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  COVID-19合并高血压患者应用ACEI或ARB类药物的临床观察
  Clinical Observation of the Application of ACEI or ARB Drugs in Patients with COVID-19 and Hypertension
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>厉</surname><given-names>运凤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>永芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>诗博</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>堃</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>倚天</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>继东</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>青岛大学经济学院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院心血管内科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院重症医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3131</fpage><lpage>3137</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：观察COVID-19合并高血压患者应用ACEI或ARB类药物的临床疗效。方法：回顾性调查于2020-02-10日至2020-02-29日收治在武汉同济医院光谷院区重症病房的200例患者的病历资料，分析统计其病例的临床资料、辅助检查及治疗方案。根据是否应用ACEI/ARB类药物进行分组，分为两组：ACEI/ARB类药物组和非ACEI/ARB类药物组(应用其他降压药物，如CCB、β受体阻滞剂、利尿剂等)。观察两组实验室检查结果(CRP、IL-6、白细胞计数、淋巴细胞计数、乳酸脱氢酶、肿瘤坏死因子-α、IgM)、核酸转阴时间、出现症状–入院时间、发病–出院时间。结果：① 性别、年龄及高血压分级ACEI/ARB组与及非ACEI/ARB组无明显差异。② 12例非ACEI/ARB组患者(48%)属于严重亚组，5例死亡。相反，在ACEI/ARB组中，5例(31.25%)属于严重亚组，5死亡。严重病例在非ACEI/ARB组的百分比高于ACEI/ARB组，但这一差异并不明显，可能是由于临床病例较少。③ ACEI/ARB组患者TNF-α及乳酸脱氢酶下降明显。其他实验室检查结果，如淋巴细胞计数、高敏C反应蛋白、IL-6、淋巴细胞比例、肌酸激酶，在两组之间无显著差异。④ 两组药物对高血压COVID-19患者疗效来看，ACEI或ARB用药影响系数为0.0989011，非ACEI或ARB用药影响系数为0.2142857，标准差分别为0.1975986和0.1423602，P值分别为0.619和0.139，说明两组药物都有助于高血压新冠肺炎患者病情好转，但临床表现需要一定时间，同时ACEI或ARB用药效果略微高于非ACEI或ARB用药，但差异不是很大。结论：研究结果支持高血压COVID-19患者服用RAAS系统抑制剂。ACEI/ARB类药物改善临床转归的机制还需进一步研究。
   Objective: To observe the clinical efficacy of ACEI or ARB drugs in patients with COVID-19 and hypertension. Methods: Retrospectively investigate the medical records of 200 patients who were admitted to the intensive care unit of the Optics Valley Hospital of Wuhan Tongji Hospital from 2020-02-10 to 2020-02-29, and analyze and count the clinical data, auxiliary examinations and treatment plans of their cases. According to whether ACEI/ARB drugs are used or not, they are divided into two groups: ACEI/ARB drug group and non-ACEI/ARB drug group (application of other antihypertensive drugs, such as CCB, beta blockers, diuretic Agent, etc.). Observe the results of two groups of laboratory tests (CRP, IL-6, white blood cell count, lymphocyte count, lactate dehydrogenase, tumor necrosis factor-α, IgM), time of nucleic acid conversion, symptoms-admission time, onset-discharge time. Results: ① There was no significant difference between the ACEI/ARB group and the non-ACEI/ARB group in gender, age and hypertension classification. ② 12 patients (48%) in the non-ACEI/ARB group belonged to the severe subgroup, and 5 died. In contrast, in the ACEI/ARB group, 5 patients (31.25%) belonged to the severe subgroup and 5 died. The percentage of severe cases in the non-ACEI/ARB group is higher than that in the ACEI/ARB group, but this difference is not significant, which may be due to fewer clinical cases. ③ The TNF-α and lactate dehydrogenase decreased significantly in the ACEI/ARB group. Other laboratory test results, such as lymphocyte count, high sensitivity C-reactive protein, IL-6, lymphocyte ratio, and creatine kinase, were not significantly different between the two groups. ④ In terms of the efficacy of the two groups of drugs on patients with hypertension and COVID-19, the coefficient of influence of ACEI or ARB medication is 0.0989011, and the coefficient of influence of non-ACEI or ARB medication is 0.2142857, with standard deviations of 0.1975986 and 0.1423602, and P values of 0.619 and 0.139, it shows that the two groups of drugs can help patients with hypertension and new coronary pneumonia to improve, but the clinical manifestations take a certain time. At the same time, the effect of ACEI or ARB medication is slightly higher than that of non-ACEI or ARB medication, but the difference is not very large. Conclusion: The research results support the use of RAAS system inhibitors for patients with hypertension and COVID-19. The mechanism of ACEI/ARB drugs to improve clinical outcome needs further study.
 
</p></abstract><kwd-group><kwd>COVID-19，高血压，肾素–血管紧张素系统，血管紧张素转换酶抑制剂，血管紧张素受体拮抗剂, COVID-19</kwd><kwd> Hypertension</kwd><kwd> Renin-Angiotensinsystem</kwd><kwd> Angiotensin Converting Enzyme Inhibitor</kwd><kwd> 
Angiotensin Receptor Antagonist</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察COVID-19合并高血压患者应用ACEI或ARB类药物的临床疗效。方法：回顾性调查于2020-02-10日至2020-02-29日收治在武汉同济医院光谷院区重症病房的200例患者的病历资料，分析统计其病例的临床资料、辅助检查及治疗方案。根据是否应用ACEI/ARB类药物进行分组，分为两组：ACEI/ARB类药物组和非ACEI/ARB类药物组(应用其他降压药物，如CCB、β受体阻滞剂、利尿剂等)。观察两组实验室检查结果(CRP、IL-6、白细胞计数、淋巴细胞计数、乳酸脱氢酶、肿瘤坏死因子-α、IgM)、核酸转阴时间、出现症状–入院时间、发病–出院时间。结果：① 性别、年龄及高血压分级ACEI/ARB组与及非ACEI/ARB组无明显差异。② 12例非ACEI/ARB组患者(48%)属于严重亚组，5例死亡。相反，在ACEI/ARB组中，5例(31.25%)属于严重亚组，5死亡。严重病例在非ACEI/ARB组的百分比高于ACEI/ARB组，但这一差异并不明显，可能是由于临床病例较少。③ ACEI/ARB组患者TNF-α及乳酸脱氢酶下降明显。其他实验室检查结果，如淋巴细胞计数、高敏C反应蛋白、IL-6、淋巴细胞比例、肌酸激酶，在两组之间无显著差异。④ 两组药物对高血压COVID-19患者疗效来看，ACEI或ARB用药影响系数为0.0989011，非ACEI或ARB用药影响系数为0.2142857，标准差分别为0.1975986和0.1423602，P值分别为0.619和0.139，说明两组药物都有助于高血压新冠肺炎患者病情好转，但临床表现需要一定时间，同时ACEI或ARB用药效果略微高于非ACEI或ARB用药，但差异不是很大。结论：研究结果支持高血压COVID-19患者服用RAAS系统抑制剂。ACEI/ARB类药物改善临床转归的机制还需进一步研究。</p></sec><sec id="s2"><title>关键词</title><p>COVID-19，高血压，肾素–血管紧张素系统，血管紧张素转换酶抑制剂，血管紧张素受体拮抗剂</p></sec><sec id="s3"><title>Clinical Observation of the Application of ACEI or ARB Drugs in Patients with COVID-19 and Hypertension<sup> </sup></title><p>Yunfeng Li<sup>1</sup>, Yongfang Guo<sup>1</sup>, Shibo Wang<sup>2</sup>, Kun Li<sup>2</sup>, Yitian Wang<sup>1</sup>, Tao Li<sup>3</sup>, Jidong Zhang<sup>1*</sup></p><p><sup>1</sup>Department of Cardiovascular Medicine, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Critical Care Medicine, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>3</sup>School of Economics, Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/35-1572389x5_hanspub.png?20210721082842791" /></p><p>Received: Jun. 12<sup>th</sup>, 2021; accepted: Jul. 1<sup>st</sup>, 2021; published: Jul. 20<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/35-1572389x6_hanspub.png?20210721082842791" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To observe the clinical efficacy of ACEI or ARB drugs in patients with COVID-19 and hypertension. Methods: Retrospectively investigate the medical records of 200 patients who were admitted to the intensive care unit of the Optics Valley Hospital of Wuhan Tongji Hospital from 2020-02-10 to 2020-02-29, and analyze and count the clinical data, auxiliary examinations and treatment plans of their cases. According to whether ACEI/ARB drugs are used or not, they are divided into two groups: ACEI/ARB drug group and non-ACEI/ARB drug group (application of other antihypertensive drugs, such as CCB, beta blockers, diuretic Agent, etc.). Observe the results of two groups of laboratory tests (CRP, IL-6, white blood cell count, lymphocyte count, lactate dehydrogenase, tumor necrosis factor-α, IgM), time of nucleic acid conversion, symptoms-admission time, onset-discharge time. Results: ① There was no significant difference between the ACEI/ARB group and the non-ACEI/ARB group in gender, age and hypertension classification. ② 12 patients (48%) in the non-ACEI/ARB group belonged to the severe subgroup, and 5 died. In contrast, in the ACEI/ARB group, 5 patients (31.25%) belonged to the severe subgroup and 5 died. The percentage of severe cases in the non-ACEI/ARB group is higher than that in the ACEI/ARB group, but this difference is not significant, which may be due to fewer clinical cases. ③ The TNF-α and lactate dehydrogenase decreased significantly in the ACEI/ARB group. Other laboratory test results, such as lymphocyte count, high sensitivity C-reactive protein, IL-6, lymphocyte ratio, and creatine kinase, were not significantly different between the two groups. ④ In terms of the efficacy of the two groups of drugs on patients with hypertension and COVID-19, the coefficient of influence of ACEI or ARB medication is 0.0989011, and the coefficient of influence of non-ACEI or ARB medication is 0.2142857, with standard deviations of 0.1975986 and 0.1423602, and P values of 0.619 and 0.139, it shows that the two groups of drugs can help patients with hypertension and new coronary pneumonia to improve, but the clinical manifestations take a certain time. At the same time, the effect of ACEI or ARB medication is slightly higher than that of non-ACEI or ARB medication, but the difference is not very large. Conclusion: The research results support the use of RAAS system inhibitors for patients with hypertension and COVID-19. The mechanism of ACEI/ARB drugs to improve clinical outcome needs further study.</p><p>Keywords:COVID-19, Hypertension, Renin-Angiotensinsystem, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Antagonist</p><disp-formula id="hanspub.43987-formula25"><graphic xlink:href="//html.hanspub.org/file/35-1572389x7_hanspub.png?20210721082842791"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/35-1572389x8_hanspub.png?20210721082842791" /> <img src="//html.hanspub.org/file/35-1572389x9_hanspub.png?20210721082842791" /></p></sec><sec id="s5"><title>1. 引言</title><p>新型冠状病毒肺炎(Corona Virus Disease 2019，COVID-19，简称新冠肺炎)是由2019年底出现的新型冠状病毒(SARS-CoV-2，曾临时称为2019-nCoV，简称新冠病毒)侵入人体呼吸道引起的肺炎 [<xref ref-type="bibr" rid="hanspub.43987-ref1">1</xref>]。SARS-CoV-2通过病毒表面的棘突蛋白(Spike蛋白，S蛋白)与呼吸道上皮细胞表面的受体血管紧张素转换酶2 (ACE2)相互结合，随后病毒包膜蛋白与细胞膜融合，病毒将遗传物质释放入细胞内，进而复制倍增，引起一系列病理改变 [<xref ref-type="bibr" rid="hanspub.43987-ref2">2</xref>]。</p><p>COVID-19患者的临床特点分析表明，高血压患者占所有患者的20%~30%，肾素–血管紧张素系统(RAAS)在高血压的发生和发展中起着重要作用，其调控主要通过两种途径，包括ACE/AngII/AT1R通路和ACE2/Ang(1-7)/Mas受体通路两种途径，ACE/AngII/AT1R通路主要作用是收缩血管、升高血压、致使肺损伤；ACE2/Ang(1-7)/Mas受体通路的主要作用是舒张血管、降低血压、抗炎、抗凝、抗纤维化。正常情况下，这两种途径处于动态平衡，共同维持血压和电解质水平的稳定。当SARS-CoV-2与ACE2结合时，使得ACE/AngII/AT1R通路和ACE2/Ang(1-7)/Mas受体通路失衡，而ACE抑制剂(ACEIs)和血管紧张素受体拮抗剂(ARBs)作为主要的抗高血压药物，既可以抑制ACE/AngII/AT1R通路也可以调节ACE2/Ang(1-7)/Mas受体通路，使两条通路处于平衡状态，维持血压的稳定 [<xref ref-type="bibr" rid="hanspub.43987-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.43987-ref4">4</xref>]。但研究表明ACEI/ARB可以上调ACE2的表达 [<xref ref-type="bibr" rid="hanspub.43987-ref5">5</xref>]，而ACE2是COVID-19感染的潜在靶点，COVID-19感染阶段容易引起病毒的入侵，而ACE2的升高又可抑制急性肺损伤的炎症反应，故COVID-19感染合并高血压是否可应用ACEI/ARB类药物缺少临床证据，此研究旨在验证COVID-19合并高血压患者应用ACEI或ARB类药物的临床效果，为进一步的诊治提供临床证据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 病例选择</title><sec id="s6_1_1"><title>2.1.1. 诊断标准</title><p>纳入标准：1、确诊为COVID-19的病人(新冠肺炎的诊断参考《新型冠状病毒肺炎诊疗方案(试行第七版)》中的有关标准。疑似病例只要具备以下病原学证据之一即可确诊纳入：① 呼吸道标本或血液标本实时光RT-PCR检测新型冠状病毒核酸阳性；② 呼吸道标本或血液标本病毒基因测序，与已知的新型冠状病毒高度同源) [<xref ref-type="bibr" rid="hanspub.43987-ref6">6</xref>]；2、确诊为原发性高血压患者(平静状态下真实收缩压 ≥ 140 mmHg和(或)舒张压 ≥ 90 mmHg)；3、患者年龄 &gt; 18周岁；4、实验室数据完整，可用于比对分析。</p></sec><sec id="s6_1_2"><title>2.1.2. 排除标准</title><p>1、排除其他疾病导致的疑似患者，例如感染呼吸道嗜肺军团菌、肺炎支原体、Q热立克次体、肺炎衣原体、腺病毒、呼吸道合胞病毒、甲型流感病毒、乙型流感病毒和副流感病毒等。2、年龄 &lt; 18周岁；3、严重恶性肿瘤患者；4、依从性差；5、数据不完整。</p></sec></sec><sec id="s6_2"><title>2.2. 观察项目和方法</title><p>回顾性调查于2020-02-10日至2020-02-29日收治在武汉同济医院光谷院区重症病房的200例患者的病历资料，分析统计其病例的临床资料、辅助检查及治疗方案。根据是否应用ACEI/ARB类药物进行分组，分为三组：分为ACEI/ARB类药物组和非ACEI/ARB类药物组(应用其他降压药物，如CCB、β受体阻滞剂、利尿剂等)。观察2组实验室检查结果(CRP、IL-6、白细胞计数、淋巴细胞计数、乳酸脱氢酶、肿瘤坏死因子-α、IgM)、核酸转阴时间、出现症状–入院时间、发病–出院时间。如果记录中缺少数据或需要澄清，则通过与主治医生和病案室医疗服务人员直接沟通获取数据。</p></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>本次实验数据使用SPSS23.0进行数据分析。对数据进行正态检验；对于服从正态或近似服从正态分布的定量资料，使用均数、标准差的形式进行描述，使用独立样本t检验；对于不服从正态分布的资料，使用中位数(上四分位数，下四分位数)进行描述，使用非参数检验进行差异性分析；使用卡方分析法(包括连续性校正法)对计数资料进行分析；使用分组回归分析，本研究认为P &lt; 0.05为具有统计学意义，本次研究均为双侧检验。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>截至2020年2月29日，共有200名COVID-19患者被华中科技大学附属同济医院光谷院区收治。在这些患者中，46例(23%)患有高血压。5例高血压患者在住院期间没有服用任何降压药物，并被排除在随后的分析之外。其他41例患者(89.13%)接受降压治疗在进一步的研究中。41例分析患者根据降压疗法分为两组：ACEI/ARB组(16例)包括使用ACEI或ARB药物治疗的患者，非ACEI/ARB组(25例)包括使用其他降压药物治疗的患者，包括钙通道阻滞剂(CCB)、β阻滞剂和利尿剂。非ACEI/ARB组13例(52%)、ACEI/ARB组10例(62.5%)有其他共患病，如2型糖尿病(T2D)和冠心病(CHD)及脑血管疾病。患者血压住院期间控制良好。</p><p>分析对象的中位年龄为68.73岁，其中51.22%为男性。ACEI/ARB组高血压分级与及非ACEI/ARB组无明显差异。两组均表现出相似的体征和症状。非ACEI/ARB组从症状发作到入院的中位天数为10.44，ACEI/ARB组为9.875。同时，非ACEI/ARB组从症状发作到出院的中位天数为30.64天，ACEI/ARB组为28.625天。非ACEI/ARB组核酸检测第一次转阴时间中位数15.14天，ACEI/ARB组为15.56天，具体内容见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of the basic situation of the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >平均值</th><th align="center" valign="middle" >标准差</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >年龄</td><td align="center" valign="middle" >ACEI/ARB组</td><td align="center" valign="middle" >69.438</td><td align="center" valign="middle" >9.494</td><td align="center" valign="middle"  rowspan="2"  >0.328</td><td align="center" valign="middle"  rowspan="2"  >0.744</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >68.280</td><td align="center" valign="middle" >11.866</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >发病–入院时间</td><td align="center" valign="middle" >ACEI/ARB组</td><td align="center" valign="middle" >9.875</td><td align="center" valign="middle" >4.161</td><td align="center" valign="middle"  rowspan="2"  >−0.344</td><td align="center" valign="middle"  rowspan="2"  >0.733</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >10.440</td><td align="center" valign="middle" >5.657</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >发病–出院时间</td><td align="center" valign="middle" >ACEI/ARB组</td><td align="center" valign="middle" >28.625</td><td align="center" valign="middle" >9.885</td><td align="center" valign="middle"  rowspan="2"  >−0.676</td><td align="center" valign="middle"  rowspan="2"  >0.503</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >30.640</td><td align="center" valign="middle" >8.939</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >TNF-α下降水平</td><td align="center" valign="middle" >ACEI/ARB组</td><td align="center" valign="middle" >13.147</td><td align="center" valign="middle" >7.084</td><td align="center" valign="middle"  rowspan="4"  >2.261</td><td align="center" valign="middle"  rowspan="4"  >0.03</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >9.200</td><td align="center" valign="middle" >3.651</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >0.977</td><td align="center" valign="middle" >0.518</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >16.324</td><td align="center" valign="middle" >11.715</td></tr></tbody></table></table-wrap><p>表1. 两组基本情况的比较</p><p>住院期间，12例非ACEI/ARB组患者(48%)属于严重亚组，5例死亡。相反，在ACEI/ARB组中，5例(31.25%)属于严重亚组，5死亡，具体内容见表2。严重病例在非ACEI/ARB组的百分比高于ACEI/ARB组，但这一差异并不明显，可能是由于临床病例较少。接下来，我们研究了服用ACEI或ARB药物对COVID-19高血压患者实验室检查结果的影响。</p><p>ACEI/ARB组患者有较高的TNF-α及乳酸脱氢酶下降水平。其他实验室检查结果，如淋巴细胞计数、高敏C反应蛋白、IL-6、淋巴细胞比例、肌酸激酶，在两组之间无显著差异，具体内容见表1，表3。我们对高血压COVID-19患者进行ACEI或ARB用药和非ACEI或ARB用药效果差异分析，从两组药物对高血压COVID-19患者疗效来看，非ACEI或ARB用药影响系数为0.0989011，ACEI或ARB用药影响系数为0.2142857，标准差分别为0.1975986和0.1423602，P值分别为0.619和0.139，具体内容见表4。说明两组药物都有助于高血压新冠肺炎患者病情好转，但临床表现需要一定时间，同时ACEI或ARB用药效果略微高于非ACEI或ARB用药，但差异不是很大。为了进一步研究所得结果的稳健性，本文加入性别和年龄做分组回归分析，估计结果与表4估计结果基本一致，从而证明之前所得结论是稳健的。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical outcome of non-ACEI/ARB medication group and ACEI/ARB medication grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >普通型</th><th align="center" valign="middle" >重型</th><th align="center" valign="middle" >死亡</th></tr></thead><tr><td align="center" valign="middle" >应用ACEIARB</td><td align="center" valign="middle" >6 (37.5%)</td><td align="center" valign="middle" >5 (31.25%)</td><td align="center" valign="middle" >5 (31.25%)</td></tr><tr><td align="center" valign="middle" >非应用ACEI或ARB</td><td align="center" valign="middle" >8 (32%)</td><td align="center" valign="middle" >12 (48%)</td><td align="center" valign="middle" >5 (20%)</td></tr></tbody></table></table-wrap><p>表2. 非ACEI/ARB用药组与ACEI/ARB用药组的临床转归</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of laboratory test results of the two drug group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >下四分位数</th><th align="center" valign="middle" >中位数</th><th align="center" valign="middle" >上四分位数</th><th align="center" valign="middle" >Z</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >IL-6水平</td><td align="center" valign="middle" >ACEI/ARB组</td><td align="center" valign="middle" >4.48</td><td align="center" valign="middle" >12.7</td><td align="center" valign="middle" >40.745</td><td align="center" valign="middle"  rowspan="2"  >−0.045</td><td align="center" valign="middle"  rowspan="2"  >0.976</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >5.19</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >30.565</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >hs-CRP水平</td><td align="center" valign="middle" >ACEI/ARB组</td><td align="center" valign="middle" >8.2</td><td align="center" valign="middle" >56.2</td><td align="center" valign="middle" >106.7</td><td align="center" valign="middle"  rowspan="2"  >−0.628</td><td align="center" valign="middle"  rowspan="2"  >0.534</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >18.3</td><td align="center" valign="middle" >27.1</td><td align="center" valign="middle" >65.05</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >核酸转阴时间</td><td align="center" valign="middle" >ACEI/ARB组</td><td align="center" valign="middle" >12.5</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >17.5</td><td align="center" valign="middle"  rowspan="3"  >−0.254</td><td align="center" valign="middle"  rowspan="3"  >0.829</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >18.5</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >68.5</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >乳酸脱氢酶下降水平</td><td align="center" valign="middle" >ACEI/ARB组</td><td align="center" valign="middle" >275</td><td align="center" valign="middle" >310</td><td align="center" valign="middle" >439.5</td><td align="center" valign="middle"  rowspan="2"  >−2.382</td><td align="center" valign="middle"  rowspan="2"  >0.017</td></tr><tr><td align="center" valign="middle" >非ACEI/ARB组</td><td align="center" valign="middle" >245</td><td align="center" valign="middle" >278</td><td align="center" valign="middle" >305</td></tr></tbody></table></table-wrap><p>表3. 两药物组各实验室检查结果的比较</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Estimation results of the efficacy of the two groups of drug</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >系数</th><th align="center" valign="middle" >标准差</th><th align="center" valign="middle" >P值</th><th align="center" valign="middle" >Pseudo R<sup>2</sup></th><th align="center" valign="middle" >观测值</th></tr></thead><tr><td align="center" valign="middle" >非ACEI或ARB用药</td><td align="center" valign="middle" >0.0989011</td><td align="center" valign="middle" >0.1975986</td><td align="center" valign="middle" >0.619</td><td align="center" valign="middle" >0.0039</td><td align="center" valign="middle" >46</td></tr><tr><td align="center" valign="middle" >ACEI或ARB用药</td><td align="center" valign="middle" >0.2142857</td><td align="center" valign="middle" >0.1423602</td><td align="center" valign="middle" >0.139</td><td align="center" valign="middle" >0.0348</td><td align="center" valign="middle" >46</td></tr></tbody></table></table-wrap><p>表4. 两组药物疗效估计结果</p></sec><sec id="s8"><title>4. 讨论</title><p>最近的证据表明，高血压COVID-19患者易发生严重病例 [<xref ref-type="bibr" rid="hanspub.43987-ref7">7</xref>]，因此，确定RAAS抑制剂对COVID-19高血压患者的影响是很重要的。RAAS抑制剂在正常人体内维持ACE/AngII/AT1R通路和ACE2/Ang(1-7)/Mas受体通路的平衡，但在COVID-19患者中使得ACE/AngII/AT1R通路和ACE2/Ang(1-7)/Mas受体通路失衡，可诱发炎症反应，造成肺损伤。但是目前已知RAS抑制剂对ACE2的影响主要是由于ACE2在心脏，肾脏和血浆中的表达，目前尚不完全清楚RAS抑制剂是否能影响气道上皮细胞ACE2的表达。此外，ACE2在高血压患者中的表达可能低于血压正常的人。到目前为止，没有证据表明使用RASS抑制剂会使患者更容易感染病毒。</p><p>研究表明，与健康的人相比，COVID-19患者增加了血管紧张素II [<xref ref-type="bibr" rid="hanspub.43987-ref8">8</xref>]。血管紧张素II的异常增加与高血压和肺衰竭有关。此外，RAS抑制剂已被证明与降低脓毒症患者的死亡率有关 [<xref ref-type="bibr" rid="hanspub.43987-ref9">9</xref>]。血管紧张素II通过激活AT1R积极调节炎性细胞因子的表达 [<xref ref-type="bibr" rid="hanspub.43987-ref10">10</xref>]。过高水平的炎性细胞因子对COVID-19患者的预后有害。因此，建议COVID-19患者使用ACEI/ARB抑制RAS是有益的。通过本实验数据可以看到，两组药物都有助于高血压COVID-19患者病情好转，但临床表现需要一定时间，同时ACEI/ARB用药效果略微高于非ACEI/ARB用药，但差异不是很大。同时在应用ACEI/ARB类药物的高血压COVID-19患者中，TNF-α及乳酸脱氢酶下降水平明显，我们发现ACEI/ARB治疗可减轻炎症反应，这与ACEI和ARB治疗减轻LPS所致肺炎损伤 [<xref ref-type="bibr" rid="hanspub.43987-ref11">11</xref>] 的结果一致。其他研究表明，在COVID-19住院的高血压患者中，随着ACEI/ARB治疗的持续使用，以及RAS激活在COVID-19高血压患者严重程度及发病机制中的作用，观察到了潜在的有益作用。与ACEI/ARB非使用者相比，ACEI/ARB住院治疗与全因死亡风险较低相关 [<xref ref-type="bibr" rid="hanspub.43987-ref12">12</xref>]。本研究结果表明，严重病例在非ACEI/ARB组的百分比高于ACEI/ARB组，但这一差异并不明显，可能是由于临床病例较少。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，此临床证据表明RAS抑制剂改善了COVID-19高血压患者的临床结果，表明这些患者可以受益于持续或优先使用ACEI/ARB进行降压治疗。因此，研究结果支持高血压COVID-19患者服用RAAS系统抑制剂。ACEI/ARB类药物改善临床转归的机制还需进一步研究。</p></sec><sec id="s10"><title>文章引用</title><p>厉运凤,郭永芳,王诗博,李 堃,王倚天,李 涛,张继东. COVID-19合并高血压患者应用ACEI或ARB类药物的临床观察Clinical Observation of the Application of ACEI or ARB Drugs in Patients with COVID-19 and Hypertension[J]. 临床医学进展, 2021, 11(07): 3131-3137. https://doi.org/10.12677/ACM.2021.117454</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43987-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">朱正保, 仲崇科, 张凯欣, 等. 中国内地新型冠状病毒肺炎流行趋势分析[J]. 中华预防医学杂志, 2020, 54(6): 620-624.</mixed-citation></ref><ref id="hanspub.43987-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Yan, R., Zhang, Y., Li, Y., et al. (2020) Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2. Science, 367, 1444-1448. &lt;br&gt;https://doi.org/10.1126/science.abb2762</mixed-citation></ref><ref id="hanspub.43987-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, R. and Boim, M.A. (2009) Diversity of Pathways for Intracellular Angiotensin II Synthesis. Current Opinion in Nephrology and Hypertension, 18, 33-39. &lt;br&gt;https://doi.org/10.1097/MNH.0b013e32831a9e20</mixed-citation></ref><ref id="hanspub.43987-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Souza, S.R.A., Oliveira, S.W., Alzamora, A.C., et al. (2018) The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiological Reviews, 98, 505-553.  
&lt;br&gt;https://doi.org/10.1152/physrev.00023.2016</mixed-citation></ref><ref id="hanspub.43987-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Abhinav, G. and Mansi, O. (2020) A Systematic Review and Meta-Analysis to Evaluate the Clinical Outcomes in COVID-19 Patients on Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. European Heart Journal of Cardiovascular Pharmacotherapy, 15, 64.</mixed-citation></ref><ref id="hanspub.43987-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第七版) [J]. 心肺血管病杂志, 2020, 39(2): 103-107.</mixed-citation></ref><ref id="hanspub.43987-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Wang, L., Yan, S., et al. (2020) Clinical Characteristics of 25 Death Cases with COVID-19: A Retrospective Review of Medical Records in a Single Medical Center, Wuhan, China. International Journal of Infectious Diseases, 94, 128-132. &lt;br&gt;https://doi.org/10.1016/j.ijid.2020.03.053</mixed-citation></ref><ref id="hanspub.43987-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Yang, Y., Zhang, C., et al. (2020) Clinical and Biochemical Indexes from 2019-nCoV Infected Patients Linked to Viral Loads and Lung Injury. Nature Public Health Emergency Collection, 63, 364-374.  
&lt;br&gt;https://doi.org/10.1007/s11427-020-1643-8</mixed-citation></ref><ref id="hanspub.43987-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hsu, W.T., Galm, B.P., Schrank, G., et al. (2020) Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Short-Term Mortality after Sepsis: A Population-Based Cohort Study. Hypertension, 75, 483-491.  
&lt;br&gt;https://doi.org/10.1161/HYPERTENSIONAHA.119.13197</mixed-citation></ref><ref id="hanspub.43987-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Khaidakov, M., Ding, Z., et al. (2012) Cross-Talk between Inflammation Andangiotensin II: Studies Based on Direct Transfection of Cardiomyocytes with AT1R and AT2R cDNA. Experimental Biology and Medicine, 237, 1394-1401. &lt;br&gt;https://doi.org/10.1258/ebm.2012.012212</mixed-citation></ref><ref id="hanspub.43987-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ye, R. and Liu, Z. (2019) ACE2 Exhibits Protective Effects against LPS-Induced Acute Lung Injury in Mice by Inhibiting the LPS-TLR4 Pathway. Experimental and Molecular Pathology, 113, Article ID: 104350.  
&lt;br&gt;https://doi.org/10.1016/j.yexmp.2019.104350</mixed-citation></ref><ref id="hanspub.43987-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, P., Zhu, L.H., et al. (2020) Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19. Circulation Research, 126, 1671-1681. &lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.120.317134</mixed-citation></ref></ref-list></back></article>